Since the 2016 announcement of the IU Grand Challenge Precision Health Initiative, important progress has been made for Indiana and its patients.
- 43 new faculty members have been recruited to the IU School of Medicine. These roles are high paying, highly influential roles in the area of research and development.
- 80 new jobs have been created as a result of faculty recruits, many of whom have also relocated their staffs to Indiana.
- New faculty - hired over the past 12 months - have brought in more than $19M in grant funding.
- Several new companies have relocated to Indiana as a result of faculty hires, such as Michael Weiss, MD, PhD, MBA, leader of the chemical biology & biotherapeutics scientific pillar, who brought his company Thermalin Diabetes, Inc. to Indiana.
- 96 peer-reviewed publications have been published by members of the Precision Health Team so far, with 30 more submitted.
- Precision genomics clinics have expanded both locally and into rural Indiana sites. This capability gives doctors the opportunity to tailor treatments to the specific individual, based on their DNA or genetics; a capability that was not previously available prior to the IU Grand Challenge Precision Health Initiative.
- First CAR-T cell therapies have been successfully administered to adult cancer patients in Indiana and were administered in an IU Health facility, IU School of Medicine’s partner health system. CAR-T cell therapies re-engineer a patient’s T-cells in order to kill cancerous cells in certain types of leukemia. CAR-T is largely considered a cure for these diseases after all other treatments have failed.